ОБ ЭТОМ ЭПИЗОДЕ

английский
США

РАСШИФРОВКА 🔗

ПОИСК ПРОШЛЫХ ЭПИЗОДОВ

Искать прошлые эпизоды The Dime.

ДРУГИЕ ЭПИЗОДЫ В ЭТОМ ПОДКАсте

When a regulator asks what the downside is of adding one more testing requirement, what is the downside? Just a little more safe. Just in case. Especially when adding one more item to an already exhaustive testing panel. That logic is how licensed cannabis markets end up buried under compliance la…
Cannabis operators aren't short on data. They're drowning in it. The real problem is what happens when that data gets handed to the wrong person, read at the wrong time, or used to justify the wrong decision. Overproduction cycles, steep discounting, margin pressure building back into manufacturing…
The cannabis industry convinced the world it had a medicine before the science caught up. Now the science is here, and almost no one is paying attention. CBD is not a panacea. When Charlotte's Web opened hearts and minds, the messaging of what it could do ran years ahead of what the data could act…
Predictable cash flow is the whole game. In cannabis, predictable is the one thing almost nobody has. Organigram CEO James Yamanaka came up over 20 years at British American Tobacco, where that discipline is the entire model. He thinks the opportunity starts there: trim the portfolio, stop chasing…
The number in your head and the number you actually need are not the same number. That gap is where most cannabis businesses break. Joe Lustberg has financed operators across the country for years and watched that gap swallow businesses that looked fine on paper. He has also spent over two years p…
Отказ от ответственности: Подкаст и иллюстрации, встроенные в эту страницу, взяты из Bryan Fields, который является собственностью его владельца и не связан или не одобрен Listen Notes, Inc.